VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COMy 2020 | Refractory multiple myeloma: analyzing MAMMOTH and STORM

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the MAMMOTH and STORM (NCT02336815) studies evaluating selinexor in refractory myeloma. The efficacy of selinexor in combination with low-dose dexamethasone was demonstrated in the pivotal Phase 2 STORM study (NCT02336815). The results of the MAMMOTH study have been used as a benchmark to refer to. Analysis of the MAMMOTH population and the STORM population saw an improvement in overall survival with selinexor in refractory patients. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.

Disclosures

Research support : Amgen, Janssen
Honorarium: BMS, Janssen, Amgen, Genentech, Astra Zeneca

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter